Treats schizophrenia. Sold as Clozaril, Fazaclo Odt, Versacloz. Every FDA application for this active ingredient: 3 branded and 13 generic.
As of Nov 15, 2026, FDA lists 16 applications for Clozapine (sold as Clozaril, Fazaclo Odt, Versacloz), first approved Sep 26, 1989, with 3 new uses approved and 0 published complete response letters.
| Clozapine | Part D | $79.3M | +1% | 67,478 |
| Clozapine ODT | Part D | $16.6M | 0% | 3,000 |
| Clozaril | Part D | $11.2M | -5% | 544 |
| Versacloz | Part D | $1.3M | -1% | 112 |
| Sequential Treatment Approaches for Treatment-Resistant SchizophreniaTreatment-resistant Schizophrenia · Shanghai Mental Health Center | Phase 3 | Recruiting | Nov 5, 2026 |
| Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side EffectsTreatment Resistant Schizophrenia, Obesity & Overweight · Faculty of Medicine, Sousse | Not applicable | Recruiting | Sep 14, 2026 |
| ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's DiseaseParkinson's Disease (PD), Parkinsonian Disorders · Qianfoshan Hospital | Phase 1 | Not yet recruiting | Jul 22, 2026 |
| No Guts No Glory ProbioticsPatients Using Olanzapine, Quetiapine, Risperidone or Clozapine · University Medical Center Groningen | Phase 2 / Phase 3 | Recruiting | May 26, 2026 |
| Clinical Study of Chemogenetic Gene Therapy With AAV for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic NucleusParkinson's Disease (PD) · Second Affiliated Hospital, Zhejiang University, School of Medicine | Early phase 1 | Not yet recruiting | Apr 16, 2026 |
| Stratification and Treatment in Early Psychosis Study -ASSISTTreatment Resistant Psychosis, Psychosis · University of Oxford | Phase 3 | Not yet recruiting | Jan 8, 2026 |
| A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's DiseaseParkinson Disease (PD), Gene Therapy · Ruijin Hospital | Early phase 1 | Not yet recruiting | Jul 25, 2025 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder · Dr. Stavroula Rakitzi | Phase 4 | Active, not recruiting | Jul 2, 2025 |
| Sep 26, 1989 | ClozarilNDA 19758 · New molecular entity | Heritage Life | 83 | Marketed |
| Aug 30, 1996 | ClozapineANDA 74546 | Sandoz | 0 | Discontinued |
| Nov 26, 1997 | ClozapineANDA 74949 | Ivax Sub Teva Pharms | 53 | Marketed |
| May 27, 1999 | ClozapineANDA 75417 | Mylan | 34 | Marketed |
| Nov 15, 2002 | ClozapineANDA 75713 | Sun Pharm Inds Inc | 27 | Discontinued |
| Feb 10, 2004 | Fazaclo OdtNDA 21590 · New dosage form | Jazz | 23 | Discontinued |
| Apr 26, 2005 | ClozapineANDA 75162 | Par Pharm | 2 | Discontinued |
| Dec 16, 2005 | ClozapineANDA 76809 | Ivax Sub Teva Pharms | 30 | Marketed |
| Feb 6, 2013 | VersaclozNDA 203479 · New dosage form | Douglas Pharms | 18 | Marketed |
| Sep 15, 2015 | ClozapineANDA 201824 | Mylan | 12 | Marketed |
| Sep 17, 2015 | ClozapineANDA 203807 | Dr Reddys Labs SA | 9 | Discontinued |
| Nov 25, 2015 | ClozapineANDA 202873 | Accord Hlthcare | 13 | Marketed |
| Nov 29, 2016 | ClozapineANDA 206433 | Aurobindo Pharma | 14 | Marketed |
| Dec 6, 2017 | ClozapineANDA 209480 | Zydus Pharms | 0 | Discontinued |
| Apr 9, 2018 | ClozapineANDA 90308 | Barr Labs Inc | 10 | Marketed |
| Dec 12, 2024 | ClozapineANDA 212923 | Aurobindo Pharma | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA